Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ann Med ; 56(1): 2357230, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38813804

RESUMO

INTRODUCTION: Understanding changes in vaccine hesitancy, overall and by sociodemographic characteristics, may highlight sub-populations for whom more intensive efforts are needed to increase vaccine uptake and confidence. METHODS: We analyzed data using the CDC's Research and Development Survey (RANDS), a nationally representative survey of U.S. adults ≥18 years, collected from 17 May 2021-30 June 2021 (n = 5,458) and 3 November 2022-12 December 2022 (n = 6,821). We assessed changes in vaccine hesitancy, changes in vaccine attitudes and attitudes, and factors associated with hesitancy toward both vaccines in general and COVID-19 vaccines among a nationally representative sample of U.S. adults. RESULTS: Although COVID-19 vaccination (≥1 dose) increased from 67.2% (2021) to 74.7% (2022), COVID-19 vaccine hesitancy increased from 40.7% to 44.6% during the same period. During the same period, hesitancy toward both COVID-19 vaccines and vaccines in general increased among those who were aged ≥65 years and who were non-Hispanic White. However, COVID-19 vaccine hesitancy decreased among non-Hispanic Black adults. Current or former smokers were more hesitant toward vaccines in general (aPR = 1.13, 95%CI: 1.03-1.24) and toward COVID-19 vaccines (aPR = 1.08, 95%CI: 1.01-1.16) compared to never smokers. Among adults who did not receive any COVID-19 vaccines, COVID-19 vaccine hesitancy increased from 86.6% in 2021 to 92.4% in 2022. Furthermore, belief in the overall social benefit of the COVID-19 vaccine decreased from 47.5% to 25.1%. CONCLUSION: This study highlights concerning trends in vaccine hesitancy and uptake of the COVID-19 and other recommended vaccines. We found that some high-risk groups (e.g. smokers) and population subgroups have become more vaccine hesitant, suggesting the need for improved and intensified strategies to increase vaccine confidence and uptake. Future research may focus on qualitative inquiry to understand specific concerns and determinants contributing to increased hesitancy among these groups to help inform interventions and communication campaigns to support vaccination.


COVID-19 vaccine hesitancy increased from 40.7% in 2021 to 44.6% in 2022.During the same period, hesitancy regarding both the COVID-19 vaccine and vaccines in general increased among those who were ≥65 years and non-Hispanic White while hesitancy toward COVID-19 vaccines decreased among non-Hispanic Black adults.Belief in the overall social benefit of the COVID-19 vaccine decreased from 47.5% to 25.1%, sug­gesting need to frame messaging on benefits such as protection from severe disease outcomes.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Hesitação Vacinal , Humanos , Vacinas contra COVID-19/administração & dosagem , Masculino , Hesitação Vacinal/estatística & dados numéricos , Hesitação Vacinal/psicologia , Adulto , Feminino , Estados Unidos/epidemiologia , Pessoa de Meia-Idade , COVID-19/prevenção & controle , COVID-19/epidemiologia , Idoso , Adulto Jovem , Adolescente , Conhecimentos, Atitudes e Prática em Saúde , SARS-CoV-2 , Inquéritos e Questionários , Vacinação/psicologia , Vacinação/estatística & dados numéricos
2.
Vaccines (Basel) ; 12(5)2024 May 07.
Artigo em Inglês | MEDLINE | ID: mdl-38793754

RESUMO

Understanding the association between booster vaccination and COVID-19 outcomes can help strengthen post-pandemic messaging and strategies to increase vaccination and reduce severe and long-term consequences of COVID-19. Using the Household Pulse Survey data collected from U.S. adults from 9 December 2022 to 13 February 2023 (n = 214,768), this study assessed the relationship between COVID-19 booster vaccination and COVID-19 outcomes (testing positive for COVID-19, moderate/severe COVID-19, and long COVID). Disparities were found in COVID-19 outcomes (e.g., testing positive for COVID-19, moderate/severe COVID-19, and long COVID) by sociodemographic characteristics, region of residence, food insecurity status, mental health status, disability status, and housing type. Receipt of a COVID-19 booster vaccination was negatively associated with testing positive for COVID-19 (aOR = 0.75, 95%CI: 0.72,0.79), having moderate/severe COVID-19 (aOR = 0.92, 95%CI: 0.88, 0.97), or having long COVID (aOR = 0.86 (0.80, 0.91)). Even among those who tested positive for COVID-19, those who received the booster vaccine were less likely to have moderate/severe COVID-19 and less likely to have long COVID. Communicating the benefits of COVID-19 booster vaccination, integrating vaccination in patient visits, and reducing access barriers can increase vaccination uptake and confidence for all individuals and protect them against the severe negative outcomes of COVID-19.

3.
Ann Med ; 55(1): 2232818, 2023 12.
Artigo em Inglês | MEDLINE | ID: mdl-37449878

RESUMO

INTRODUCTION: Despite recommendations for COVID-19 primary series completion and booster doses for children and adolescents, coverage has been less than optimal, particularly in some subpopulations. This study explored disparities in childhood/adolescent COVID-19 vaccination, parental intent to vaccinate their children and adolescents, and reasons for non-vaccination in the US. METHODS: Using the U.S. Census Bureau's Household Pulse Survey (HPS), we analyzed households with children aged <18 years using data collected from September 14 to November 14, 2022 (n = 44,929). Child and adolescent COVID-19 vaccination coverage (≥1 dose, completed primary series, and booster vaccination) and parental intentions toward vaccination were assessed by sociodemographic characteristics. Factors associated with child and adolescent vaccination coverage were examined using multivariable regression models. Reasons for non-vaccination were assessed overall, by the child's age group and respondent's age group. RESULTS: Overall, approximately half (50.1%) of children aged < 18 years were vaccinated against COVID-19 (≥1 dose). Completed primary series vaccination was 44.2% among all children aged <18 years. By age group, completed primary series was 13.2% among children <5 years, 43.9% among children 5-11 years, and 63.3% among adolescents 12-17 years. Booster vaccination among those who completed the primary series was 39.1% among children 5-11 years and 55.3% among adolescents 12-17 years. Vaccination coverage differed by race/ethnicity, educational attainment, household income, region, parental COVID-19 vaccination status, prior COVID-19 diagnosis, child's age group, and parental age group. Parental reluctance was highest for children aged <5 years (46.8%). Main reasons for non-vaccination among reluctant parents were concerns about side effects (53.3%), lack of trust in COVID-19 vaccines (48.7%), and the belief that children do not need a COVID-19 vaccine (38.8%). CONCLUSION: Disparities in COVID-19 vaccination coverage among children and adolescents continue to exist. Further efforts are needed to increase COVID-19 primary series and booster vaccination and parental confidence in vaccines.


Using survey data collected from September 14 to November 14, 2022, COVID-19 vaccination coverage was low among children and adolescents. Overall, approximately half (50.1%) of the children aged <18 years were vaccinated against COVID-19 (≥1 dose). Completed primary series vaccination was 44.2% among all children aged < 18 years. By age group, completed primary series was 13.2% among children <5 years, 43.9% among children 5­11 years, and 63.3% among adolescents 12­17 years. Booster vaccination, among those who completed the primary series, was 39.1% among children 5­11 years and 55.3% among adolescents 12­17 years.Vaccination coverage differed by race/ethnicity, educational attainment, household income, region, parental COVID-19 vaccination status, prior COVID-19 diagnosis, child's age group, and parental age group.Parental reluctance was the highest for children aged <5 years (46.8%), followed by children 5­11 years (35.8%) and adolescents 12­17 years (23.5%).Main reasons for non-vaccination among reluctant parents were concerns about side effects (53.3%), lack of trust in COVID-19 vaccines (48.7%), the belief that children do not need a COVID-19 vaccine (38.8%), lack of trust in the government (35.6%), and that children in the household were not members of a high-risk group (32.8%).Disparities in COVID-19 vaccination coverage among children and adolescents continue to exist. Further efforts are needed to increase COVID-19 primary series and booster vaccination and parental confidence in vaccines.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Criança , Adolescente , Humanos , Cobertura Vacinal , Intenção , Teste para COVID-19 , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinação , Pais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...